Increasing Treatment Rates for Hepatitis C in Primary Care

References

1. 1.↵
   Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. World Health Organization. 2021. Available from: https://www.who.int/publications/i/item/9789240027077. Accessed December, 2021.
2. 2.↵
   1. Kwong JC,
   2. Crowcroft NS,
   3. Campitelli MA,
   4. et al

   . Ontario Burden of Infectious Disease Study. ICES Publications 2010.
3. 3.↵
   1. Shah H,
   2. Bilodeau M,
   3. Burak KW

   . Canadian Association for the Study of the Liveret al. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. CMAJ. 2018;190:E677–E687.

   OpenUrlFREE Full Text
4. 4.↵
   1. Mason K,
   2. Dodd Z,
   3. Sockalingam S,
   4. et al

   . Beyond viral response: a prospective evaluation of a community-based, multi-disciplinary, peer-driven model of HCV treatment and support. Int J Drug Policy 2015;26:1007–13.

   OpenUrlPubMed
5. 5.↵
   1. Mason K,
   2. Dodd Z,
   3. Guyton M,
   4. et al

   . Understanding real-world adherence in the directly acting antiviral era: a prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada. Int J Drug Policy 2017;47:202–8.

   OpenUrlPubMed
6. 6.↵
   1. Kattakuzhy S,
   2. Gross C,
   3. Emmanuel B

   , ASCEND Providerset al. Expansion of treatment for Hepatitis C virus infection by task shifting to community-based nonspecialist providers: a nonrandomized clinical trial. Ann Intern Med 2017;167:311–8.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. von Aesch Z,
   2. Craig-Neil A,
   3. Shah H,
   4. Antoniou T,
   5. Meaney C,
   6. Pinto AD

   . Family medicine-directed hepatitis C care and barriers to treatment: a mixed-methods study. CMAJ Open 2021;9:E201–e207.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Thorne S,
   2. Kirkham SR,
   3. MacDonald-Emes J

   . Interpretive description: a noncategorical qualitative alternative for developing nursing knowledge. Res Nurs Health 1997;20:169–77.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Shadish WR Jr.,
   2. Cook TD,
   3. Leviton LC

   . Foundations of program evaluation: theories of practice. Thousand Oaks, CA, US: Sage Publications, Inc; 1991.
10. 10.↵
    1. Nilsen P,
    2. Bernhardsson S

    . Context matters in implementation science: a scoping review of determinant frameworks that describe contextual determinants for implementation outcomes. BMC Health Serv Res 2019;19:189.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Kaplan HC,
    2. Brady PW,
    3. Dritz MC,
    4. et al

    . The influence of context on quality improvement success in health care: a systematic review of the literature. Milbank Q 2010;88:500–59.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Lakhan P,
    2. Askew D,
    3. Hayman N,
    4. Pokino LA,
    5. Sendall C,
    6. Clark PJ

    . Optimising Hepatitis C care in an urban Aboriginal and Torres Strait Islander primary health care clinic. Aust N Z J Public Health 2019;43:228–35.

    OpenUrl
13. 13.↵
    1. Read P,
    2. Lothian R,
    3. Chronister K,
    4. et al

    . Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. Int J Drug Policy 2017;47:209–15.

    OpenUrlPubMed
14. 14.↵
    1. Nickoloff S,
    2. Linn K,
    3. Winter S

    . Treating hepatitis C in the family medicine office. American Family Physician 2019. Available from: https://www.aafp.org/pubs/afp/issues/2019/0815/p248.html. Accessed December, 2021.
15. 15.↵
    1. Woodward EN,
    2. Matthieu MM,
    3. Uchendu US,
    4. Rogal S,
    5. Kirchner JE

    . The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment. Implement Sci 2019;14:26.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Lobo R,
    2. Mascarenhas L,
    3. Worthington D,
    4. Bevan J,
    5. Mak DB

    . Evaluation of the regional nurse-supported hepatitis C shared care program in Western Australia: a mixed methods study. BMC Health Serv Res 2015;15:399.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Vu TM,
    2. Toribio W,
    3. Riazi F,
    4. et al

    . Increasing access to hepatitis C virus medications: a program model using patient navigators and specialty pharmacy to obtain prior authorization approval. J Manag Care Spec Pharm 2018;24:329–33.

    OpenUrl
18. 18.↵
    1. Lasser KE,
    2. Heinz A,
    3. Battisti L,
    4. et al

    . A hepatitis C treatment program based in a safety-net hospital patient-centered medical home. Ann Fam Med 2017;15:258–61.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Rosenthal ES,
    2. Silk R,
    3. Mathur P,
    4. et al

    . Concurrent initiation of hepatitis c and opioid use disorder treatment in people who inject drugs. Clin Infect Dis 2020;71:1715–22.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Radley A,
    2. de Bruin M,
    3. Inglis SK,
    4. Donnan PT,
    5. Dillon JF

    . Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial. BMJ Open 2018;8:e021443.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Lee KS,
    2. Quintiliani L,
    3. Heinz A,
    4. et al

    . A financial incentive program to improve appointment attendance at a safety-net hospital-based primary care hepatitis C treatment program. PLoS One 2020;15:e0228767.

    OpenUrl
22. 22.↵
    1. Himelhoch S,
    2. McCarthy JF,
    3. Ganoczy D,
    4. et al

    . Understanding associations between serious mental illness and hepatitis C virus among veterans: a national multivariate analysis. Psychosomatics 2009;50:30–7.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. McMahon BJ,
    2. Townshend-Bulson L,
    3. Homan C,
    4. et al

    . Cascade of care for Alaska Native people with chronic hepatitis c virus infection: statewide program with high linkage to care. Clin Infect Dis 2020;70:2005–7.

    OpenUrl
24. 24.↵
    1. Belperio PS,
    2. Chartier M,
    3. Ross DB,
    4. Alaigh P,
    5. Shulkin D

    . Curing hepatitis C virus infection: best practices from the U.S. Department of Veterans Affairs. Ann Intern Med 2017;167:499–504.

    OpenUrl
25. 25.↵
    1. Castro R,
    2. Perazzo H,
    3. de Araujo L,
    4. Gutierres IG,
    5. Grinsztejn B,
    6. Veloso VG

    . Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: A systematic review with meta-analysis. PLoS One 2020;15:e0229143.

    OpenUrlPubMed
26. 26.↵
    1. Yakovchenko V,
    2. Miech EJ,
    3. Chinman MJ,
    4. et al

    . Strategy configurations directly linked to higher hepatitis C virus treatment starts: an applied use of configurational comparative methods. Med Care 2020;58:e31–e38.

    OpenUrlCrossRefPubMed